コンテンツへスキップ
Merck
  • Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.

Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2015-04-10)
Samuel W Cramer, Laurentiu S Popa, Russell E Carter, Gang Chen, Timothy J Ebner
要旨

The Ca(2+) channelopathies caused by mutations of the CACNA1A gene that encodes the pore-forming subunit of the human Cav2.1 (P/Q-type) voltage-gated Ca(2+) channel include episodic ataxia type 2 (EA2). Although, in EA2 the emphasis has been on cerebellar dysfunction, patients also exhibit episodic, nonmotoric abnormalities involving the cerebral cortex. This study demonstrates episodic, low-frequency oscillations (LFOs) throughout the cerebral cortex of tottering (tg/tg) mice, a widely used model of EA2. Ranging between 0.035 and 0.11 Hz, the LFOs in tg/tg mice can spontaneously develop very high power, referred to as a high-power state. The LFOs in tg/tg mice are mediated in part by neuronal activity as tetrodotoxin decreases the oscillations and cortical neuron discharge contain the same low frequencies. The high-power state involves compensatory mechanisms because acutely decreasing P/Q-type Ca(2+) channel function in either wild-type (WT) or tg/tg mice does not induce the high-power state. In contrast, blocking l-type Ca(2+) channels, known to be upregulated in tg/tg mice, reduces the high-power state. Intriguingly, basal excitatory glutamatergic neurotransmission constrains the high-power state because blocking ionotropic or metabotropic glutamate receptors results in high-power LFOs in tg/tg but not WT mice. The high-power LFOs are decreased markedly by acetazolamide and 4-aminopyridine, the primary treatments for EA2, suggesting disease relevance. Together, these results demonstrate that the high-power LFOs in the tg/tg cerebral cortex represent a highly abnormal excitability state that may underlie noncerebellar symptoms that characterize CACNA1A mutations.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
臭化水素酸, ACS reagent, 48%
Supelco
クロロメタン 溶液, 200 μg/mL in methanol, analytical standard
Sigma-Aldrich
モノクロナール抗α-チューブリン マウス宿主抗体, ascites fluid, clone B-5-1-2
Sigma-Aldrich
臭化水素酸, reagent grade, 48%
Sigma-Aldrich
インドメタシン, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
臭化水素 溶液, 33 wt. % in acetic acid
Sigma-Aldrich
臭化水素酸 溶液, 33 wt. % in acetic acid
Sigma-Aldrich
臭化水素酸, 48 wt. % in H2O, ≥99.99%
Sigma-Aldrich
カフェイン, anhydrous, 99%, FCC, FG
Sigma-Aldrich
インドール, ≥99%
Sigma-Aldrich
4-アミノピリジン, 98%
Sigma-Aldrich
4-アミノピリジン, ≥99%
USP
カフェイン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
ピリジン 塩酸塩, 98%
Sigma-Aldrich
カフェイン, powder, ReagentPlus®
Sigma-Aldrich
DL-2-アミノ-5-ホスホノペンタン酸, solid
Supelco
カフェイン, Pharmaceutical Secondary Standard; Certified Reference Material
USP
カフェイン融点標準品, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
アセタゾールアミド, ≥99%, powder
Sigma-Aldrich
インドメタシン, meets USP testing specifications
Sigma-Aldrich
インドール, ≥99%, FG
Sigma-Aldrich
クロロメタン 溶液, 1.0 M in tert-butyl methyl ether, anhydrous
Sigma-Aldrich
DNQX, ≥98% (TLC)
Sigma-Aldrich
クロロメタン 溶液, 1.0 M in diethyl ether
Supelco
カフェイン, Pharmaceutical Secondary Standard; Certified Reference Material
USP
インドメタシン, United States Pharmacopeia (USP) Reference Standard
USP
アセタゾールアミド, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
カフェイン, Sigma Reference Standard, vial of 250 mg
Supelco
融点スタンダード235~237°C, analytical standard
Supelco
カフェイン, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland